Jan 10, 2025 · Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for oncology, immunology, neuroscience, and infectious diseases to patients in China and around the world.

Zai Lab is a patient-focused, innovative, commercial-stage, global biopharmaceutical company based in China and the U.S. We are focused on bringing best-in-class and first-in-class medicines for oncology, immunology, neuroscience, and infectious diseases to patients in greater China and around the world.

Find the latest Zai Lab Limited (ZLAB) stock quote, history, news and other vital information to help you with your stock trading and investing.

With deep market insights, strong local relationships and extensive industry experience, Zai Lab remains committed to delivering innovative products and improving their accessibility and affordability for patients in greater China, and eventually globally.

2 days ago · About Zai Lab. Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering ...

2 days ago · Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and ...

Jan 14, 2025 · Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, …

In September 2020, Zai Lab announced the detailed positive results from the NORA study, showing ZEJULA demonstrated significant progression-free survival (PFS) benefit for patients in China with platinum-sensitive, recurrent ovarian cancer, regardless of biomarker status. In NORA, niraparib treatment resulted in a 68% reduction in the risk of ...

2 days ago · Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, …

Jun 11, 2024 · Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D